Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemophilia B with Inhibitor Clear all
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

NCT02270918
View directory record Official record
Conditions
Thrombosis
Interventions
Kcentra, Apixaban, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 30, 2026, 5:21 AM EDT
Recruiting Phase 4 Interventional

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

NCT04647227
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 30, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

NCT03417102
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, Bypassing agents
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 30, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

NCT00245245
View directory record Official record
Conditions
Hemophilia A
Interventions
recombinant porcine coagulation factor VIII (OBI-1)
Drug
Lead sponsor
Octagen Corporation
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Sep 30, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 74 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 30, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

NCT00851721
View directory record Official record
Conditions
Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
4 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 30, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537
View directory record Official record
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 30, 2026, 5:21 AM EDT
Completed No phase listed Observational

ATHN 7: Hemophilia Natural History Study

NCT03619863
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 30, 2026, 5:21 AM EDT
Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
BAY86-6150, eptacog alfa [activated]
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 62 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Sacramento, California • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 30, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
marstacimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 5:21 AM EDT
Completed No phase listed Observational

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

NCT03818529
View directory record Official record
Conditions
Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
0 Years to 13 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Phoenix, Arizona • Madera, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 30, 2026, 5:21 AM EDT
Terminated Phase 3 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

NCT04489537
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
MarzAA
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Sep 30, 2026, 5:21 AM EDT